Details of the Drug Formulations

General Information of Drug (ID: DMRDZ4X)

Drug Name
Dabigatran etexilate Drug Info
Synonyms
BIBR-1048; 211915-06-9; Dabigatran etexilate mesilate; ethyl N-[(2-{[(4-{N'-[(hexyloxy)carbonyl]carbamimidoyl}phenyl)amino]methyl}-1-methyl-1H-benzimidazol-5-yl)carbonyl]-N-pyridin-2-yl-beta-alaninate; Dabigatran etexilate methanesulfonate; BIBR-1048 (Dabigatran); UNII-2E18WX195X; BIBR1048; BIBR-1048-BS-RS1; CHEBI:70746; 2E18WX195X; cc-72; DSSTox_CID_31470; DSSTox_RID_97355; DSSTox_GSID_57681; SCHEMBL505829; DTXSID4057681; Dabigatran etexilate (USAN/INN); MolPort-016-633-287; EBD35035; Tox21_113924; BDBM504
Indication
Disease Entry ICD 11 Status REF
Venous thromboembolism BD72 Phase 3 [1]
Cross-matching ID
PubChem CID
135565674
CAS Number
211915-06-9
TTD ID
D0KI5R
INTEDE ID
DR0400
ACDINA ID
D00162

Full List of Drug Formulations Containing This Drug

Dabigatran etexilate 150 mg capsule
Company Formulation ID FDA Description
Rebel Distributors F05201 Butyl alcohol; Fd&c blue no. 2; Fd&c yellow no. 6; Isopropyl alcohol; Potassium chloride; Tartaric acid; Ferrosoferric oxide; Propylene glycol; Talc; Titanium dioxide; Water; Acacia; Alcohol; Carrageenan; Dimethicone; Hydroxypropyl cellulose; Hypromelloses; Methyl alcohol; Shellac
------------------------------------------------------------------------------------
Dabigatran Etexilate Mesylate eq 110mg base capsule
Company Formulation ID FDA Description
Boehringer Ingelheim F23950 Acacia; Dimethicone; Hypromellose; Hydroxypropyl Cellulose; Talc; Tartaric Acid; Carrageenan; Hypromellose; Potassium Chloride; Titanium Dioxide; Black Edible Ink; Fd&C Blue No. 2
------------------------------------------------------------------------------------
Dabigatran Etexilate Mesylate eq 150mg base capsule
Company Formulation ID FDA Description
Boehringer Ingelheim F23951 Acacia; Dimethicone; Hypromellose; Hydroxypropyl Cellulose; Talc; Tartaric Acid; Carrageenan; Hypromellose; Potassium Chloride; Titanium Dioxide; Black Edible Ink; Fd&C Blue No. 2
------------------------------------------------------------------------------------
Dabigatran Etexilate Mesylate eq 75mg base capsule
Company Formulation ID FDA Description
Boehringer Ingelheim F23416 Acacia; Dimethicone; Hypromellose; Hydroxypropyl Cellulose; Talc; Tartaric Acid; Carrageenan; Hypromellose; Potassium Chloride; Titanium Dioxide; Black Edible Ink
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)